Alumis Inc. Common Stock (ALMS) Stock Price
ALMSStock
$6.12+32.75%52W
Market Cap$792.14M
P/E—
PEG Ratio—
Div yield—
Beta1.26
ALMS Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-83.17%
Price vs S&P 500 (4W)-21.21%
VGM Score26.74
ALMS Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.71 | -$0.79 | -11.30%(-$0.08) | |
| Q1 2026 | -$0.83 | -$0.74 | +10.48%(+$0.09) | |
| Q4 2025 | -$0.98 | -$0.25 | +74.16%(+$0.72) | |
| Q3 2025 | -$1.00 | -$1.06 | -6.00%(-$0.06) | |
| Q2 2025 | -$1.39 | -$1.47 | -6.10%(-$0.08) |
ALMS Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.35
4.35
4.38
4.38
Industry Peers — Pharmaceuticals(574)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
ALMSAlumis Inc. Common Stock | D | F | D | 144.4x | — | — | — | $6.12 |
| LLYEli Lilly & Co. | D | B | A | 14.9x | 49.6% | 83.4% | 27.6% | $1257.03 |
| JNJJohnson & Johnson | D | C | B | 6.2x | 7.8% | 67.7% | 14.9% | $255.56 |
| ABBVABBVIE INC. | D | C | A | 7.8x | 10.4% | 72.8% | -2.9% | $285.42 |
| MRKMerck & Co., Inc. | D | C | A | 5.4x | 4.6% | 77.3% | 21.2% | $145.95 |
| NVSNovartis AG | C | C | B | 4.9x | 3.3% | 75.0% | 15.3% | $150.62 |
| AZNAstraZeneca PLC | C | B | B | 4.3x | 8.6% | 81.3% | 21.9% | $165.41 |
| ABTAbbott Laboratories | C | C | B | 3.9x | 8.1% | 56.8% | 8.2% | $104.89 |
| NVONovo-Nordisk A/S | B | C | C | 3.5x | 5.6% | 80.7% | 20.7% | $38.83 |
| PFEPfizer Inc. | C | D | A | 2.6x | -0.2% | 74.7% | -3.5% | $29.58 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | 10.1x | 10.2% | 86.0% | 8.3% | $499.74 |
About Alumis Inc. Common Stock
Alumis Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for autoimmune disorders. Leveraging its proprietary precision data analytics platform, the company aims to replace broad immunosuppression with more specific therapeutic approaches. Its pipeline includes drug candidates targeting TYK2 and IRF5 pathways.